Author:
Bahl A.,Oudard S.,Tombal B.,Özgüroĝlu M.,Hansen S.,Kocak I.,Gravis G.,Devin J.,Shen L.,de Bono J.S.,Sartor; A.O.
Reference23 articles.
1. ZMalikGdi LorenzoMBasaranCabazitaxel (Cbz) + prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): interim results from compassionate-use programme (CUP) and early-access programme (EAP). European Society of Medical Oncology Congress28 September–2 October, 2012 Vienna, AustriaPoster 931P
2. JEVTANA® (cabazitaxel) Injection, Summary of Product Characteristics;Sanofi,2013
3. Sanofi U.S. LLCJEVTANA® (cabazitaxel) Injection, Prescribing InformationBridgewater, NJ, USA, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf (4 April 2013, date last accessed)
4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010
5. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer;Oudard;Future Oncol,2011
Cited by
133 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献